Phase 2 trial in 75 adults with moderate to severe atopic dermatitis in China: ICP-332 80 mg or 120 mg for 4 weeks had adverse event rates similar to placebo (76%, 75% vs 68%, all mild or moderate) and cut EASI by 78.2% and 72.5% vs 16.7%.
RCTn = 75
Xu et al. Safety and Efficacy of ICP-332 for Moderate to Severe Atopic Dermatitis: A Phase 2 Randomized Clinical Trial